Show items per page
Elements: 5
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective Boonen, Steven; Ferrari, Serge Livio; Miller, Paul D; Eriksen, Erik F; ... Cosman, Felicia 2012
add to browser selection
Romosozumab Treatment in Postmenopausal Women with Osteoporosis Cosman, Felicia; Crittenden, Daria B.; Adachi, Jonathan D.; Binkley, Neil; ... Grauer, Andreas 2016
add to browser selection
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis Bone, Henry G; Cosman, Felicia; Miller, Paul D; Williams, Gregory C; ... Saag, Kenneth G 2018
add to browser selection
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome Cosman, Felicia; Crittenden, Daria B; Ferrari, Serge Livio; Lewiecki, E Michael; ... Grauer, Andreas 2018
add to browser selection
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab Cosman, Felicia; Crittenden, Daria B; Ferrari, Serge Livio; Khan, Aliya; ... Grauer, Andreas 2018